AestheticsFeatured ArticlesPhotoprotectionSkin of Color

Impact of Iron-Oxide Containing Formulations Against Visible Light-Induced Skin Pigmentation in Skin of Color Individuals

By September 9, 2020September 14th, 2020No Comments

Featured Article

Featured Article

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen.

Read more

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen.

Hawasatu Dumbuya PhD, Pearl E Grimes MD, Stephen Lynch PhD, Kalli Ji PhD, Manisha Brahmachary PhD, Qian Zheng Md PhD, Charbel Bouez PhD, Janet Wangari-Talbot PhD

 

 

Visible light (400–700nm), which contributes to 45% of solar radiation, contributes to skin darkening and worsening of dyschromias, particularly in individuals with Fitzpatrick skin phototypes III and higher.

The pathogenesis of melasma is incompletely understood, which poses a challenge for disease management. Causative factors include genetics, ultraviolet (UV) radiation, cosmetics, pregnancy, hormonal therapy, phototoxic drugs, and various medications.

Currently, sunscreens provide limited protection against that spectrum. Due to their capabilities in absorbing, scattering, and reflecting visible light, topical products containing pigments and/or metal oxides can provide additional photoprotection.

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen. Expert grading and colorimetry demonstrated that the iron-oxide containing formulations significantly protected against visible light-induced pigmentation compared to untreated skin or mineral SPF 50+ sunscreen in Fitzpatrick IV individuals.

Read Full Article Now
Article Cited in this Post

Open Access Articles

The Journal of Drugs in Dermatology (JDD) presents Open Access content, unrestricted access to our original articles, award-winning case studies, clinical trial reviews and clearance updates, drugs and devices, and special content geared toward medical residents and other allied health professionals.
Articles are reviewed by the Editorial Board of renowned experts, from key opinion leaders to well-known clinicians. View our open-access dermatology articles now.
View All Open Access Articles

You May Also Like

A Study of Glabellar Contraction Patterns in African Descendants

| Aesthetics, Featured Articles, The Latest | No Comments
Glabellar Contraction Patterns in Black Patients: Implications for Botulinum Toxin Treatment Botulinum toxin is widely used for treating dynamic glabellar lines, but contraction patterns in Black patients had not been…
Journal of Drugs in Dermatology JDD Article About Gene Analysis of Biostimulators: Poly-L-Lactic Acid Triggers Regeneration While Calcium Hydroxylapatite Induces Inflammation Upon Facial Injection.

Gene Analysis of Biostimulators: Poly-L-Lactic Acid Triggers Regeneration While Calcium Hydroxylapatite Induces Inflammation Upon Facial Injection

| Aesthetics, Featured Articles, The Latest | No Comments
Comparing Biostimulatory Agents for Skin Rejuvenation Injectable biostimulators like poly-L-lactic acid (PLLA-SCA™) and calcium hydroxylapatite (CaHA-R) are used to stimulate collagen production in aging skin, but their molecular effects differ.…
Journal of Drugs in Dermatology JDD Article About Assessing the Landscape of AI-Powered Patient Documentation in Dermatology.

Assessing the Landscape of AI-Powered Patient Documentation in Dermatology

| Featured Articles, Social and Technology | No Comments
AI-Powered Documentation: A Burnout Solution for Dermatologists Burnout among US dermatologists has surged to 49% in 2023, with administrative tasks like charting and paperwork driving professional fatigue. AI-powered patient documentation…

Leave a Reply